Core Viewpoint - HaiXi Pharmaceutical (02637) has successfully completed its IPO subscription, raising significant interest with an oversubscription of 3113 times the initial public offering amount of HKD 993.6 million [1] Group 1: IPO Details - The company raised HKD 309.4 billion in margin financing from brokers during the subscription period from October 9 to 14 [1] - HaiXi Pharmaceutical plans to issue 11.5 million H-shares, with 10% allocated for public offering at a price range of HKD 69.88 to HKD 86.4 per share [1] - The expected listing date is October 17, with Huatai International and CMB International serving as joint sponsors [1] Group 2: Business Overview - HaiXi Pharmaceutical is a commercial-stage pharmaceutical company engaged in research, development, production, and sales, with a pipeline of innovative drugs under development [1] - The company has a portfolio of generic drugs targeting various diseases, including gastrointestinal, cardiovascular, endocrine, neurological, and inflammatory diseases, with 15 generic drugs approved by the National Medical Products Administration [1] - Four of these generic drugs are included in the national volume-based procurement (VBP) program [1] Group 3: Innovative Drug Pipeline - The innovative drug pipeline includes a cancer drug, an oral medication for wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO), along with two other drugs in preclinical stages for cancer and respiratory diseases [2] - The most advanced drug, C019199 for osteosarcoma, is set to enter Phase III trials in the second half of this year [2] Group 4: Financial Projections - The company's projected revenues for 2022, 2023, 2024, and the five months ending May 31, 2025, are RMB 212.5 million, RMB 316.6 million, RMB 466.7 million, and RMB 249.2 million, respectively [2] - Corresponding gross profits are projected to be RMB 172.1 million, RMB 263.6 million, RMB 387.2 million, and RMB 209.3 million for the same periods [2] Group 5: Use of Proceeds - Approximately 52% of the net proceeds from the fundraising will be allocated to ongoing research and development to advance the drug pipeline [3] - 23% will enhance research capabilities and seek collaboration opportunities, while 8% will improve commercialization capabilities and expand market influence [3] - The remaining funds will be used for optimizing research and production systems (7%) and for working capital and other general corporate purposes (10%) [3]
海西新药招股结束 孖展认购资金达3094亿港元 超购3113倍